Proven, visionary management is critical in our pursuit of solutions that help pharmaceutical manufacturers release new breakthroughs faster, safer, and more efficiently for patients worldwide.
President and CEO
Rob has more than 20 years of leadership experience. Before joining Rapid Micro Biosystems, he was Vice President and General Manager, Americas, for the Microbiology Division of Thermo Fisher Scientific.
Previously, Rob was the VP of Global Strategy, Marketing, and Business Development for Fisher Scientific. He has also held senior positions at McKesson Corporation and its affiliates, including EVP Operations and Development and National Vice President of Sales and Business Development.
Earlier in his career, Rob was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army.
Rob holds a BS in Economics from the United States Military Academy at West Point and an MBA from Columbia University, where he was the Dr. Donald Bibeault Scholar.
Chief Financial Officer
Sean has over 25 years of broad financial experience in the healthcare and technology industries. Most recently, he served as Vice President, Finance and Controller of Asia Pacific, Middle East and Africa (AMEA) for Boston Scientific, a manufacturer of medical devices. In this role, he led all aspects of financial management for the AMEA region, as well as providing regional oversight for the strategic pricing, reimbursement, supply chain, and business development functions.
Previously he served as Vice President of Investor Relations at Boston Scientific, in progressive roles at Varian, Inc. including Vice President and Controller and Vice President, Finance and Treasurer, and as Corporate Controller at Quova. Sean began his career with PricewaterhouseCoopers, serving emerging, high growth clients across the healthcare and technology industries.
Sean holds a BS in Accounting from the Carroll School of Management at Boston College. He is a Certified Public Accountant and a member of Financial Executives International (FEI) and the Association of Financial Professionals (AFP).
Chief Commercial Officer
Andy is a global commercial executive and biopharmaceutical scientist with nearly 20 experience leading global sales and customer service teams. He will lead our global sales and service teams to help Rapid Micro Biosystems achieve its vision of being the trusted standard in microbial automation enabling our customers to deliver essential products.
Andy joins Rapid Micro Biosystems from Quanterix where he served as their SVP, Global Commercial Operations. He started his career as a field application specialist and has demonstrated his knowledge and expertise in sales leadership roles at SomaLogic and Molecular Devices. In these roles, he has demonstrated commercial revenue. Andy served his country with the US Navy. He also holds a Master’s degree in Biomedical Science from University of Massachusetts Medical School and a Bachelor’s degree in Chemistry from Southern Illinois University.
Chief Human Resources Officer
Vicki is a global human resources executive with 25 years of progressive HR experience across multiple industries, where she has been effective at impacting business results and culture change by aligning business and people strategies. She has a strong track record of designing and implementing HR operating models to attract and develop high-performing teams.
Vicki has held such positions as Chief People Officer, Chief Human Resources Officer, Vice President of Talent Management and Development with SimpliSafe, Skyworks Solutions, and ThermoFisher Scientific, respectively. She has built her career by working in high growth companies, helping the leadership teams develop scalable and sustainable talent strategies to support the business objectives.
Vicki holds a master's degree in Organizational Psychology from William James College, and a BA from Clark University. She sits on the advisory board for the George Washington University Transformative Leadership in Disruptive Times Certificate Program.
Chief Operating Officer
John has over 20 years of progressive experience to RMB from Medtronic and Becton Dickinson, where he was most recently the Vice President Global Operations. John has held multiple leadership positions in quality, operational excellence, global operations, product development, and direct day-to-day plant management activities.
John has served his country in the U.S. Army. He holds a BSBM from University of Phoenix and an MBA from University of San Francisco.
Senior Vice President of Strategy
Gurinder brings 20+ years of corporate and financial strategy, business development, and investment experience to RMB. He joins the company from Advent International, a highly successful global, growth-oriented private equity firm where, over 12 years, he grew his career from Principal to Partner & Managing Director. He led numerous private equity investments, where he closely partnered with management teams and developed strategies to drive significant organic and inorganic revenue and earnings growth.
Prior to Advent, Gurinder spent five years at Bain Capital where he built his career from Associate to Vice President. He started his career at Credit Suisse, where he was an analyst on the investment banking team.
Gurinder holds an MBA from the Harvard Business School, and an HBA from the Richard Ivey School of Business at the University of Western Ontario in Canada.
Senior Vice President and General Counsel
Jonathan leads all aspects of RMB's global legal and compliance activities. He joined the company from Insulet, where he served as the Deputy General Counsel for six years. Prior to joining Insulet, he built nearly 20 years of progressive experience in several roles including Associate General Counsel and Senior Corporate Counsel at Medtronic (previously Covidien), as well as Deputy General Counsel at Alliance Energy and Associate Director, Corporate Counsel at Publicis (formerly Digitas).
Jonathan holds a BA from Colby College, an MS in Finance from Suffolk University, and a JD from Suffolk University.
Vice President of Research & Development
Kris leads all aspects of new product design and development at Rapid Micro Biosystems. She joined the company from Ecolab, where she held progressive leadership positions across Research and Development, Engineering, Supply Chain and Quality over a period spanning nearly twenty years.
Kris holds an Executive Development Program Certificate from Wharton Business School, a Management Development Program Certificate from University of North Carolina and a BS in Mechanical Engineering from University of Texas.
Managing Director, Bain Capital Life Sciences
Jeffrey Schwartz is a Managing Director of Bain Capital Life Sciences, where he is a founding member of the team. Prior to co-founding Bain Capital Life Sciences in 2016, he was a leader within the healthcare vertical of Bain Capital Private Equity. He currently is a board member of Hugel, QuVa Pharma, and Springworks Therapeutics. Since joining Bain Capital, Mr. Schwartz has been actively involved in a wide spectrum of healthcare companies in which Bain Capital Private Equity has made investments
Prior to joining Bain Capital, Mr. Schwartz served as an Equity Research Analyst at Lehman Brothers, working in both New York and London.
Mr. Schwartz received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a BA in economics.
President and CEO, Rapid Micro Biosystems
Rob has more than 20 years of leadership experience. Before joining Rapid Micro Biosystems, he was Vice President and General Manager, Americas, for the Microbiology Division of Thermo Fisher Scientific.
Previously, Rob was the VP of Global Strategy, Marketing, and Business Development for Fisher Scientific. He has also held senior positions at McKesson Corporation and its affiliates, including EVP Operations and Development and National Vice President of Sales and Business Development.
Earlier in his career, Rob was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army.
Rob holds a BS in Economics from the United States Military Academy at West Point and an MBA from Columbia University, where he was the Dr. Donald Bibeault Scholar.
Independent Director
Managing Director, Longitude Capital
David Hirsch is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice.
Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization, and managed care strategy.
Dr. Hirsch currently serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitude's investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).
Dr. Hirsch holds a PhD in Biology from Massachusetts Institute of Technology, an MD from Harvard Medical School, and a BA in Biology from The Johns Hopkins University.
Managing Partner, Quaker Partners
Richard has more than 30 years of financial, operational and business development experience in the healthcare industry. Richard is currently Chief Financial Officer and Chief Business Officer of Reaction Biology Corporation, a provider of drug discovery services. Richard also serves as Managing Partner of Quaker Partners, a healthcare-focused venture capital and growth equity firm with $700 million under management, where he has led investments and served as an active Chairman or board member of more than a dozen private and publicly traded companies, including Rapid Micro Biosystems.
Prior to joining Reaction Biology, Richard was President and Chief Financial Officer of Strongbridge Biopharma (NASDAQ:SBBP), a commercial stage rare disease pharmaceutical company which was acquired by Xeris Pharmaceuticals in late 2021. Previously, he held positions in sales, marketing, global business development, and venture capital at GlaxoSmithKline (GSK) and its corporate venture arm, S.R. One.
Richard began his career as a Certified Public Accountant initially with KPMG, and his practice had a significant emphasis on the healthcare and emerging businesses sectors.
Richard is an adjunct faculty member at Lehigh University and Chairman of the board of directors for Restorative Therapies. Richard holds an MBA and a certificate degree in the graduate program in health administration and policy from the University of Chicago and a BA in Business Administration and Accounting from Franklin and Marshall College.
Independent Director
Nat Ricciardi spent his entire 39-year career at Pfizer Inc., retiring in 2011. At retirement, he held the positions of President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc.
In addition to Mr. Ricciardi's corporate leadership role, he was directly responsible for all of Pfizer’s internal and external supply organization, a global enterprise with as many as 38,000 employees and more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition, and animal health products. He played a leadership role in shaping a mission-driven and values-based culture as the company went through phases of growth, mergers, and acquisitions and transformation. His relentless focus on Quality and Compliance became a competitive advantage.
Mr. Ricciardi earned a degree in Chemical Engineering from the City College of New York (CCNY) and an MBA in Finance and International Business from Fordham University. He serves on the Board of Directors of Dynavax Technologies, Inc., Asterias Biotherapeutics, Inc., and is on the Strategic Advisory Board of HealthCare Royalty Partners.
Senior Talent Advisor, Danaher Corporation
Inese Lowenstein serves in a part-time role as Senior Talent Advisor to Danaher Corporation with over 20 years of business and leadership experience in life science, diagnostic and high-tech material industries. She is passionate about developing people and creating an engaged and inclusive corporate culture. Prior to her current role, Ms. Lowenstein was President of SCIEX, a Danaher company, where she delivered strong results by building highly performing teams and driving commercial execution, customer-focused innovation, and strategic M&A. Prior to her role as President, Ms. Lowenstein was the Senior Vice President of Global Sales & Service at SCIEX. Prior to joining Danaher, she held roles of increasing responsibility at Merck KGaA and EMD Millipore, most recently as an Executive Vice President, Head of Display Materials Business Unit.
Ms. Lowenstein holds a Bachelor of Economics, Engineering Science from Riga Technical University, Latvia, and an MBA from Walter A. Haas School of Business, University of California at Berkeley.